.png){kind=small}
Building on breakthroughs in Artificial Intelligence (AI), Machine Learning (ML) and graph-based technologies, DeepLife is developing innovative systems to generate new scientific hypotheses - and to validate them.
Crucial challenges in the drug development process include pinpointing biomarkers linked to specific disease states or clinical results, uncovering targets for new drugs, and assessing how cells react or become toxic in response to treatments or mutations.
Harnessing curated data from OmicStore, as well as cutting-edge algorithms, foundational models, and network-based analyses; we are building the next generation of predictive tools in DeepLife Discovery Engine to overcome these critical hurdles in drug development.
Identifying a promising therapeutic target or disease-related gene is one thing, but comprehending its role at the cellular level is vital.
Cell Blueprint transforms cellular network visualisation and interpretation, allowing users to effortlessly locate key molecules and their interacting partners within the cell.
Cell Blueprint's pioneering layout displays only direct high-quality interactions, as well as their directionality, helping users avoid interaction hairballs and focus on only the most relevant information to accelerate biological understanding and hypothesis validation.
DeepLife is a biotech company with a mission to build the next generation of system biology. We work in a highly collaborative translational manner, to facilitate the transition of discoveries from laboratory to patients.